In the present study, we developed a gemcitabine-incorporated GPC3-specific single-stranded DNA aptamer, G12msi, as an aptamer-based drug delivery vehicle for targeted therapy of advanced HCC. Here, GPC3 is linked to hepatocellular carcinoma.